AB0425 CONVERSE RELATIONSHIP OF URIC ACID AND VITAMIN D3 IN ADULT BAHRAINI PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: Adla Hassan, Eman Farid, Shaima Madeni, Diab Diab, Ola Al- Segai
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> The relationship between serum levels of uric acid (UA) and serum vitamin D3 (25(OH)D) in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) has been revealed separately. However, a possible link between these two factors in RA in comparison to SLE has not been clarified yet. This is the first study investigating the joint association between 25(OH)D and UA in two related rheumatic diseases in Bahrain. <h3>Objectives:</h3> We aimed to evaluate the possible correlation between serum UA and serum 25(OH)D in adult Bahraini patients with RA and SLE and to examine if there are any differences or similarities between these two patient's groups. <h3>Methods:</h3> Eighty adult Bahraini patients (RA=30 and SLE=50) were included in this longitudinal study (two-time points). The mean age of the patients was 45.21 years (range 16–77 years, SD=14.82). Females were 70 (87.5%). Only data for serum UA taken at the same time with vitamin D3 before and after vitamin D3 therapy were collected retrospectively from the patients' records at Salmanyia Medical Complex, Bahrain. The patients received oral vitamin D therapy at a dose of 50.000 IU weekly for 3 months. <h3>Results:</h3> Our results showed that in our studied group the mean serum level of 25(OH)D was significantly increased from 48.17 at baseline to 78.87nmol/l after therapy with an increment of 30.71 (P&lt;0.0001). Conversely, the mean serum level of UA in our cohort was significantly decreased from 333.26 at baseline to 304.67µmol/l after therapy (P&lt;0.001). When segregated the group by disease: The mean serum level of 25(OH)D was significantly increased in SLE from 38.39 at baseline to 72.41 nmol/l after therapy (P=0.000), similarly in RA patients 25(OH)D was significantly increased from 61.67 at baseline to 87.03nmol/l after therapy (P=0.002). In SLE serum UA decreased after vitamin D3 therapy, but the difference was not significant, while in RA the mean serum UA was significantly decreased from 309.83 to 262.03 after therapy (P=0.001). The SLE patients had statistically significant lower serum levels of 25(OH)D at baseline compared to RA (p=0.000). Conversely, RA patients had statistically significant lower serum levels of UA after vitamin D3 therapy compared to SLE (p=0.016). Age group &gt;40 years had significant lower serum UA than those &lt;40 before (p=0.015) and after therapy (p=0.037) <h3>Conclusion:</h3> Our study showed that vitamin D3 therapy brought about 1.5 and 2.0 folds increment in its mean serum level in RA and SLE patients, respectively. RA patients showed more reduction in serum uric acid after vitamin D3 therapy compared to SLE, however, similar results manifested by age group&gt;40 years compared to age group &lt;40 yrs. The current study established that serum 25(OH)D levels were inversely correlated with serum uric acid levels in adult Bahraini patients with RA and SLE, thus, the correction of hypovitaminosis resulted in reduction of serum UA. <h3>References</h3> [1] Costenbader, K.H., et al., Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis, 2008. 67(4): p. 530-5 [2] Jebakumar, A.J., et al., Occurrence of gout in rheumatoid arthritis: it does happen! A population-based study. Int J Clin Rheumtol. 8(4): p. 433-437 <h3>Disclosure of Interests:</h3> None declared